English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Medicine Clinical Trials
Avance Clinical首席执行官谈论了“美国生物技术行业的绿色新苗”和一份新的CRO报告
Feb 28, 2024 17:00 HKT
Avance Clinical執行長談論了「美國生物技術產業的綠色新苗」和一份新的CRO報告
Feb 28, 2024 17:00 HKT
Avance Clinical CEO는 US 바이오 기술 부문에 대한 "초록색 나무순"과 새로운 CRO 보고서에 대해 SCRIP와 대화했습니다
Feb 28, 2024 17:00 HKT
LYC Healthcare Reports Strong Q3 FY2024 Results of RM36.0 Million
Feb 28, 2024 09:34 HKT
Avance Clinical CEO Talks with SCRIP about US Biotech Sector "Green Shoots" and a New CRO Report
Feb 28, 2024 08:00 HKT
최신 분석에 따르면 미국의 바이오테크 기업 중 65%가 적절한 CRO파트너를 식별하는 데 어려움을 겪고 있습니다
Jan 17, 2024 09:00 HKT
最新的分析显示,65%的美国生物技术公司在寻找合适的合同研究机构(CRO)合作伙伴方面面临困难
Jan 16, 2024 19:00 HKT
最新的分析顯示,65%的美國生技公司在尋找合適的合約研究機構(CRO)合作夥伴方面面臨困難
Jan 16, 2024 19:00 HKT
Latest Analysis Reveals 65% of US Biotechs Struggle to Identify Suitable CRO Partner
Jan 12, 2024 16:00 HKT
冠科美博在中国完成复发或难治性急性髓细胞白血病uproleselan药物的三期临床桥接研究入组
Jan 03, 2024 20:10 HKT
冠科美博在中國完成復發或難治性急性髓細胞白血病uproleselan藥物的三期臨床橋接研究入組
Jan 03, 2024 20:09 HKT
아방스 클리니컬, 45개의 한국 생명 공학 기업 초청해 한국과 호주에서 미국으로 이어지는 글로벌레디 신약 개발 경로에 대한 설명회 개최
Oct 19, 2023 18:00 HKT
Avance Clinical Invited to Brief 45 Korean Biotechs on Their GlobalReady Drug Development Pathway from Korea and Australia to the US
Oct 19, 2023 09:00 HKT
HanchorBio and Henlius Announce Strategic Collaboration to Develop Innovative Immunotherapies
Aug 28, 2023 20:23 HKT
HanchorBio and Henlius Announce Strategic Collaboration to Develop Innovative Immunotherapies
Aug 28, 2023 19:30 HKT
WholisticResearch Reveals the Best Nootropics of 2023
Aug 18, 2023 06:00 HKT
Asensus Surgical Continues to Spearhead Innovations and Growth in Surgical Robotics
Aug 17, 2023 21:00 HKT
亿胜生物公布2023年中期业绩 收入同比增长37.1% 净利润同比增长22.0%
Aug 16, 2023 19:08 HKT
億勝生物公佈2023年中期業績 收入同比增長37.1% 淨利潤同比增長22.0%
Aug 16, 2023 19:07 HKT
Essex Bio-Technology Posts Sound 2023 Interim Financial Results, Revenue Up 37.1%, Profit Up 22%
Aug 16, 2023 19:06 HKT
Next >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: